Johnson & Johnson’s new generation of disposable pressure monitoring radiofrequency ablation catheter (QDOT Micro Diagnostic/Ablation Deflectable Tip Catheter) has recently been officially launched in China with the approval of the State Drug Administration. The catheter brings a new and innovative solution to the treatment of atrial fibrillation.
Atrial fibrillation, also known as “atrial fibrillation”, is a common tachyarrhythmia disease and has become a cardiovascular disease with the highest incidence rate in my country. Atrial fibrillation may not only lead to sudden cardiac death, heart failure and other heart-related complications, but also increase the risk of stroke by 5 times, causing significant damage to the quality of life of patients. According to statistics, there are currently more than 20 million patients in China. As the age increases, the incidence of atrial fibrillation increases sharply, and the prevalence rate of people aged 75-84 even reaches 12%. Catheter radiofrequency ablation is currently one of the main treatments for atrial fibrillation, that is, a radiofrequency ablation catheter is inserted into the heart through minimally invasive puncture, and then radiofrequency energy is released to ablate the lesion. For a long time, the progress and innovation of atrial fibrillation diagnosis and treatment technology has been the focus of attention in the industry. QDOT Micro provides a set of innovative solutions for the treatment of atrial fibrillation, bringing good news to Chinese patients with atrial fibrillation.
Johnson & Johnson Medical Technology has always been committed to improving the technology and standardized development of atrial fibrillation treatment in China. With the support of national policies, Johnson & Johnson Medical Technology continues to accelerate the introduction of innovative products and surgical solutions into China. “At the third CIIE in 2020, QDOT Micro ushered in its first show in China. Two years later, QDOT Micro was officially approved, marking another innovation milestone for Johnson & Johnson Medical Technology in the field of cardiac electrophysiology.” Johnson & Johnson Dr. Chen Xi, general manager of the Cardiovascular and Professional Solutions Division of Medical Technology China, said, “With the acceleration of the aging process in China and the gradual increase in the treatment needs of patients, we will continue to accelerate the introduction of innovative products in the field of electrophysiology. Navigation systems, ablation catheters and energy transmitters, mapping catheters, three-dimensional intracardiac ultrasound catheters and other products to create integrated solutions for arrhythmia diseases, and to provide standardized training for physicians with multiple forces to jointly promote high-quality electrophysiology development, and escort the cardiovascular and cerebrovascular health of the Chinese people.”
